Martin Silverstein

Mana joins the hec­tic fight against sol­id tu­mors with an ‘off-the-shelf’ can­di­date an­gling for an IND this year

The hunt for ef­fec­tive ther­a­pies for sol­id tu­mors has heat­ed up in ear­ly 2021 with a string of biotechs tout­ing big in­vestor checks and name-brand col­lab­o­ra­tions to chase those hard-to-treat lumps. Now, with one of its can­di­dates al­ready in the clin­ic for leukemia, Mana Ther­a­peu­tics is tak­ing a new round of fund­ing to join the fray.

On Fri­day, Mana un­veiled a $35 mil­lion Se­ries A fi­nanc­ing round that will help push the Boston-area biotech’s lead can­di­date through a Phase I tri­al and could help the com­pa­ny se­cure an IND for an off-the-shelf al­lo­gene­ic mol­e­cule tar­get­ing trans­plant-in­el­i­gi­ble AML and sol­id tu­mors with­in the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA